Bowen, J.2015-10-302015-10-302014Scientifica, 2014; 2014:194185-1-194185-62090-908X2090-908Xhttp://hdl.handle.net/2440/95947Targeted therapy of cancer is often associated with clinically significant diarrhoea; however, the mechanisms underpinning this adverse effect are currently unknown. Diarrhoea following treatment with tyrosine kinase inhibitors (TKIs) of EGFR is particularly troublesome. Until recently, understanding of EGFR TKI-induced diarrhoea has been limited to clinical observation. However, our group has recently developed the first rat model of EGFR TKI-induced diarrhoea. This paper reviews the published and unpublished findings.en© 2014 Joanne M. Bowen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal article003000946110.1155/2014/194185114104Bowen, J. [0000-0003-0876-0031]